Real-world treatment patterns and outcomes among patients (pts) with second-line (2L) and third-line (3L) metastatic triple-negative breast cancer (mTNBC) in England using the Cancer Analysis System (CAS).

被引：0
|
作者：
Chang, Lawrence
Hall, Peter S.
Preger, Luciana
Sjekloca, Nikoleta
Bergamaco, Estevan
Broe, Anne
Petrova, Plamena
Berg, Paul
Reich, Adam
Pawar, Neha
Gharaibeh, Mahdi
机构：
[1] Gilead Sci Inc, Foster City, CA USA
[2] Univ Edinburgh, Inst Genet & Canc, Edinburgh, Scotland
[3] Genentech Inc, South San Francisco, CA USA
[4] IQVIA, London, England
[5] IQVIA, Sofia, Bulgaria
[6] IQVIA, La Crosse, WI USA
[7] IQVIA, Gurgaon, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1075
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies
    Davies, Jessica
    Patel, Manali
    Gridelli, Cesare
    de Marinis, Filippo
    Waterkamp, Daniel
    McCusker, Margaret E.
    PLOS ONE, 2017, 12 (04):
  • [42] Avelumab as second-line or later (2L+) treatment (tx) in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Real-world tx patterns in France
    Fily, A. Blom
    Mortier, L.
    Van Hille, B.
    Samimi, M.
    Luciani, L.
    Cahuzac, C.
    Robert, C.
    Quereux, G.
    Maubec, E.
    Maillard, C.
    Miotti, H.
    Aubin, F.
    Lenormand, C.
    Solbes, M-N.
    Modeste, A. B. Duval
    Kachaner, I.
    Lebbe, C.
    Dutriaux, C.
    Saiag, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S687 - S687
  • [43] Sacituzumab Govitecan as a Second-Line Treatment in Relapsed/Refractory Metastatic Triple-Negative Breast Cancer Patients: A Systematic Review and Meta-analysis
    Kathpalia, Meghavi
    Sharma, Anurag
    Kaur, Navkiran
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (01) : 44 - 53
  • [44] Canadian (CAN) real-world outcomes for relapsed/recurrent (R/R) metastatic triple-negative breast cancer (mTNBC) in the first-line or later (1L+) setting by early or late recurrence status
    Cumaraswamy, A. Anna
    Boyne, Devon J.
    Henning, Jan-Willem
    Ntalla, Ioanna
    Brenner, Darren
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Sacituzumab Govitecan for Second and Subsequent Line Palliative Treatment of Patients with Triple-Negative Breast Cancer: A Polish Real-World Multicenter Cohort Study
    Puskulluoglu, Miroslawa
    Pieniazek, Malgorzata
    Las-Jankowska, Manuela
    Streb, Joanna
    Ziobro, Marek
    Pacholczak-Madej, Renata
    Kilian-Van Miegem, Paulina
    Rudzinska, Agnieszka
    Grela-Wojewoda, Aleksandra
    Lacko, Aleksandra
    Jarzab, Michal
    Polakiewicz-Gilowska, Anna
    ONCOLOGY AND THERAPY, 2024, 12 (04) : 787 - 801
  • [46] Treatment patterns and outcomes of patients with metastatic colorectal cancer in third-line and beyond systemic therapy: Real-world data from a setting with limited resources
    Jacome, Alexandre A.
    Gil, Roberto Almeida
    de Moraes, Eduardo Dias
    Peixoto, Renata D'Alpino
    Canedo, Jorge Alexandre
    Passarini, Thais
    Gil, Mariana
    Pereira, Sabrina
    Amorim, Larissa
    Prolla, Gabriel
    Freitas, Laura
    Coelho, Fernanda
    Paiva, Isabela
    Paes, Rafael
    Cruz, Heloisa
    Costa e Silva, Matheus
    Ferreira, Carlos Gil
    Ferrari, Bruno Lemos
    Garicochea, Bernardo
    Dienstmann, Rodrigo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [47] Aspire to ASCENT: Real-world outcomes from patients with metastatic triple-negative breast cancer (mTNBC) treated with Sacituzumab govitecan (Saci) in a single academic institution
    Walsh, E. M.
    Klar, M.
    Abuhadra, N.
    Robson, M.
    Drago, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S359 - S359
  • [48] A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice
    Varghese, Della
    Cruz, Giovanna I.
    Johanson, Colden
    Toland, Liz
    Miranda, Miguel
    Faherty, Eleanor C.
    Harland, David
    Kaplan, Henry G.
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (06) : 780 - 789
  • [49] Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
    Fabi, Alessandra
    Carbognin, Luisa
    Botticelli, Andrea
    Paris, Ida
    Fuso, Paolo
    Savastano, Maria Cristina
    La Verde, Nicla
    Strina, Carla
    Pedersini, Rebecca
    Guarino, Stefania
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Raffaele, Mimma
    Beano, Alessandra
    Franco, Antonio
    Valerio, Maria Rosaria
    Verderame, Francesco
    Fontana, Andrea
    Haspinger, Eva Regina
    Caldara, Alessia
    Di Leone, Alba
    Tortora, Giampaolo
    Giannarelli, Diana
    Scambia, Giovanni
    NPJ BREAST CANCER, 2023, 9 (01)
  • [50] Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
    Alessandra Fabi
    Luisa Carbognin
    Andrea Botticelli
    Ida Paris
    Paola Fuso
    Maria Cristina Savastano
    Nicla La Verde
    Carla Strina
    Rebecca Pedersini
    Stefania Guarino
    Giuseppe Curigliano
    Carmen Criscitiello
    Mimma Raffaele
    Alessandra Beano
    Antonio Franco
    Maria Rosaria Valerio
    Francesco Verderame
    Andrea Fontana
    Eva Regina Haspinger
    Alessia Caldara
    Alba Di Leone
    Giampaolo Tortora
    Diana Giannarelli
    Giovanni Scambia
    npj Breast Cancer, 9 (1)
12345